SCHEMBL3971049

SCHEMBL3971049

Cc1nc2ccc(N3CCCCC3)cc2c(-c2ccc(F)cc2)c1C(C)Oc1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 4/20 0.41
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
IDO2 Q6ZQW0 1/20 0.38
MCHR1 Q99705 2/20 0.36
FABP3 P05413 1/20 0.36
FABP4 P15090 1/20 0.36
FABP5 Q01469 1/20 0.36
KDM4E B2RXH2 1/20 0.35
PIK3CA P42336 1/20 0.35
APP P05067 3/20 0.35
HTR1A P08908 1/20 0.35
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35
HRH1 P35367 1/20 0.35
DRD3 P35462 1/20 0.35
TMEM97 Q5BJF2 1/20 0.35
SIGMAR1 Q99720 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4139157 0.92 MET (0.41) FGFR1IDO1TDO2IDO2KDM4E
SCHEMBL4139178 0.92 APP (0.41) FGFR1IDO1TDO2IDO2KDM4E
SCHEMBL4071227 0.91 IDO1 (0.40) FGFR1IDO1TDO2IDO2KDM4E
SCHEMBL13881532 0.91 IDO1 (0.38) FGFR1IDO1TDO2IDO2KDM4E
SCHEMBL4075958 0.89 KDM4E (0.38) FGFR1IDO1TDO2IDO2KDM4E
SCHEMBL3964275 0.88 IDO1 (0.40) FGFR1IDO1TDO2IDO2
SCHEMBL4147074 0.87 IDO1 (0.37) FGFR1IDO1TDO2IDO2MCHR1
SCHEMBL4131807 0.87 SOS1 (0.38) FGFR1IDO1TDO2IDO2
SCHEMBL13881922 0.86 FGFR1 (0.38) FGFR1IDO1TDO2IDO2KDM4E
SCHEMBL4143703 0.85 FGFR1 (0.39) FGFR1IDO1TDO2IDO2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088441-A1 Quinoline Compounds ASTRAZENECA AB (SE) 2009-04-02 US claimed
WO-2009041904-A1 QUINOLINE COMPOUNDS HAVING AN ACTIVITY AGAINST THE GABAB RECEPTOR ASTRAZENECA AB (SE) 2009-04-02 WO disclosed
US-20090088441-A1 Quinoline Compounds ASTRAZENECA AB (SE) 2009-04-02 US disclosed
US-20090088441-A1 Quinoline Compounds ASTRAZENECA AB (SE) 2009-04-02 US disclosed
US-20090088441-A1 Quinoline Compounds ASTRAZENECA AB (SE) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088441-A1 Quinoline Compounds GABRB1, HRH2, GABRA5 FGFR1 1291/4885IDO1 996/4885TDO2 2448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.